Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- magnesium carbonate
- Truseltiq (infigratinib)
Interactions between your drugs
magnesium carbonate infigratinib
Applies to: magnesium carbonate, Truseltiq (infigratinib)
By reducing the acidity level in the stomach, magnesium carbonate may interfere with the absorption of infigratinib and reduce its effectiveness. You should generally take infigratinib at least 2 hours before or 2 hours after magnesium carbonate. Talk to your doctor or pharmacist if you have questions on how to take these or other medications you are prescribed. It is important to tell your doctor about all other medication you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
infigratinib food
Applies to: Truseltiq (infigratinib)
Infigratinib should be taken on an empty stomach, at least 1 hour before or 2 hours after food. Do not consume grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with infigratinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of infigratinib. This may increase the frequency and severity of serious side effects such as infections; decreased red blood cell, white blood cell, and platelet counts; fever; abdominal pain; increased blood calcium and phosphate levels above normal; eye and vision problems; mouth sores and inflammation; diarrhea; redness, swelling, peeling or tenderness, mainly on the hands and feet ('hand-foot syndrome'); nails separating from the bed or poor formation of the nail; and changes in kidney function blood tests. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Carafate
Carafate is an anti-ulcer medication used to treat active duodenal ulcers. Learn about side ...
Renvela
Renvela (sevelamer) reduces blood levels of phosphorus in people with chronic kidney disease who ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Ibsrela
Ibsrela (tenapanor) is used for the treatment of irritable bowel syndrome with constipation ...
Velphoro
Velphoro (sucroferric oxyhydroxide) is used to treat hyperphosphatemia in chronic kidney disease ...
Auryxia
Auryxia is used for hyperphosphatemia of renal failure, iron deficiency anemia
Xphozah
Xphozah (tenapanor) is a phosphate absorption inhibitor that is used lower serum phosphorus levels ...
Fosrenol
Fosrenol (lanthanum carbonate) reduces phosphate levels in patients with end stage renal disease ...
Renagel
Renagel (sevelamer) is used to reduce levels of phosphorus in people with kidney disease who are on ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.